Published in Behav Brain Res on May 09, 2009
Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver. Neuron (2013) 2.32
N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia? Brain Res Bull (2010) 1.98
Sensory processing in schizophrenia: neither simple nor intact. Schizophr Bull (2009) 1.49
Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia. Schizophr Bull (2012) 1.33
GABAergic mechanisms of hippocampal hyperactivity in schizophrenia. Schizophr Res (2014) 0.98
Epidural Auditory Event-Related Potentials in the Rat to Frequency and duration Deviants: Evidence of Mismatch Negativity? Front Psychol (2011) 0.97
Nicotine ameliorates NMDA receptor antagonist-induced deficits in contextual fear conditioning through high-affinity nicotinic acetylcholine receptors in the hippocampus. Neuropharmacology (2010) 0.91
Glutamatergic gene expression is specifically reduced in thalamocortical projecting relay neurons in schizophrenia. Biol Psychiatry (2011) 0.91
Impairments of motor-cortex responses to unilateral and bilateral direct current stimulation in schizophrenia. Front Psychiatry (2013) 0.82
Deficits in emotional learning and memory in an animal model of schizophrenia. Behav Brain Res (2012) 0.82
Mismatch negativity (MMN) in freely-moving rats with several experimental controls. PLoS One (2014) 0.80
Antipsychotic treatment modulates glutamate transport and NMDA receptor expression. Eur Arch Psychiatry Clin Neurosci (2014) 0.79
A mouse model of the 15q13.3 microdeletion syndrome shows prefrontal neurophysiological dysfunctions and attentional impairment. Psychopharmacology (Berl) (2016) 0.77
Effects of chronic oral treatment with aripiprazole on the expression of NMDA receptor subunits and binding sites in rat brain. Psychopharmacology (Berl) (2011) 0.76
The antipsychotic-like effects in rodents of the positive allosteric modulator Lu AF21934 involve 5-HT1A receptor signaling: mechanistic studies. Psychopharmacology (Berl) (2014) 0.76
Electrophysiological Endophenotypes for Schizophrenia. Harv Rev Psychiatry (2016) 0.76
Animal Models of Psychosis: Current State and Future Directions. Curr Behav Neurosci Rep (2014) 0.76
The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull (1987) 51.07
What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry (1996) 11.03
Theta oscillations in the hippocampus. Neuron (2002) 10.77
The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry (2008) 9.00
Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry (1991) 8.10
Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med (2007) 7.24
Dynamic brain sources of visual evoked responses. Science (2002) 7.06
The N1 wave of the human electric and magnetic response to sound: a review and an analysis of the component structure. Psychophysiology (1987) 6.64
An oscillatory hierarchy controlling neuronal excitability and stimulus processing in the auditory cortex. J Neurophysiol (2005) 6.39
The mismatch negativity (MMN) in basic research of central auditory processing: a review. Clin Neurophysiol (2007) 5.55
Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci (1997) 5.30
Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell (1999) 4.93
NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res (2000) 4.66
NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci (2007) 4.35
The neural basis of the blood-oxygen-level-dependent functional magnetic resonance imaging signal. Philos Trans R Soc Lond B Biol Sci (2002) 3.74
Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science (1998) 3.70
Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci U S A (1996) 3.28
Working memory impairments in schizophrenia: a meta-analysis. J Abnorm Psychol (2005) 3.26
Theta oscillations in somata and dendrites of hippocampal pyramidal cells in vivo: activity-dependent phase-precession of action potentials. Hippocampus (1998) 3.23
Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab (2003) 3.21
The role of oscillations and synchrony in cortical networks and their putative relevance for the pathophysiology of schizophrenia. Schizophr Bull (2008) 3.09
Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A (1997) 3.00
Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab (2000) 2.95
GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia. Schizophr Bull (2008) 2.81
The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry (1997) 2.63
The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology (1988) 2.51
Mismatch negativity in schizophrenia: a meta-analysis. Schizophr Res (2005) 2.41
Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. Am J Psychiatry (2008) 2.33
Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry (1999) 2.27
Subcortical visual dysfunction in schizophrenia drives secondary cortical impairments. Brain (2006) 2.26
Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Arch Gen Psychiatry (2000) 2.26
Role of cortical N-methyl-D-aspartate receptors in auditory sensory memory and mismatch negativity generation: implications for schizophrenia. Proc Natl Acad Sci U S A (1996) 2.22
Evoked potentials recorded from the auditory cortex in man: evaluation and topography of the middle latency components. Electroencephalogr Clin Neurophysiol (1994) 2.18
Auditory attention--focusing the searchlight on sound. Curr Opin Neurobiol (2007) 2.11
Neurophysiological biomarkers for drug development in schizophrenia. Nat Rev Drug Discov (2008) 2.05
A specific role for NR2A-containing NMDA receptors in the maintenance of parvalbumin and GAD67 immunoreactivity in cultured interneurons. J Neurosci (2006) 1.93
Neural dynamics and the fundamental mechanisms of event-related brain potentials. Cereb Cortex (2004) 1.88
Mismatch negativity deficits are associated with poor functioning in schizophrenia patients. Arch Gen Psychiatry (2005) 1.87
Brain generators implicated in the processing of auditory stimulus deviance: a topographic event-related potential study. Psychophysiology (1990) 1.82
The mismatch negativity in cognitive and clinical neuroscience: theoretical and methodological considerations. Biol Psychol (2006) 1.78
Separate time behaviors of the temporal and frontal mismatch negativity sources. Neuroimage (2000) 1.78
Specific tonotopic organizations of different areas of the human auditory cortex revealed by simultaneous magnetic and electric recordings. Electroencephalogr Clin Neurophysiol (1995) 1.76
The neural circuitry of pre-attentive auditory change-detection: an fMRI study of pitch and duration mismatch negativity generators. Cereb Cortex (2004) 1.73
Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide. Biol Psychiatry (2004) 1.71
Early-stage visual processing deficits in schizophrenia. Curr Opin Psychiatry (2005) 1.71
Neuromagnetic source localization of auditory evoked fields and intracerebral evoked potentials: a comparison of data in the same patients. Clin Neurophysiol (2001) 1.69
COMT genotype predicts cortical-limbic D1 receptor availability measured with [11C]NNC112 and PET. Mol Psychiatry (2008) 1.63
Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology (2007) 1.61
Properties of the evoked potential generators: current source-density analysis of visually evoked potentials in the cat cortex. Int J Neurosci (1987) 1.57
High-precision neuromagnetic study of the functional organization of the human auditory cortex. Audiol Neurootol (1998) 1.56
Decrement of the N1 auditory event-related potential with stimulus repetition: habituation vs. refractoriness. Int J Psychophysiol (1998) 1.54
Imaging dopamine transmission in schizophrenia. A review and meta-analysis. Q J Nucl Med (1998) 1.52
P50 sensory gating ratios in schizophrenics and controls: a review and data analysis. Psychiatry Res (2008) 1.52
Mismatch negativity: an index of a preattentive processing deficit in schizophrenia. Biol Psychiatry (1991) 1.48
Detection of stimulus deviance within primate primary auditory cortex: intracortical mechanisms of mismatch negativity (MMN) generation. Brain Res (1994) 1.46
Adaptive modeling of the unattended acoustic environment reflected in the mismatch negativity event-related potential. Brain Res (1996) 1.44
Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatry (2000) 1.43
Deficits in auditory and visual context-dependent processing in schizophrenia: defining the pattern. Arch Gen Psychiatry (2000) 1.41
Distinct contributions of glutamate and dopamine receptors to temporal aspects of rodent working memory using a clinically relevant task. Psychopharmacology (Berl) (2001) 1.38
Intracerebral sources of human auditory-evoked potentials. Audiol Neurootol (1999) 1.38
Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers. Biol Psychiatry (2002) 1.29
Positive allosteric modulation of metabotropic glutamate 5 (mGlu5) receptors reverses N-Methyl-D-aspartate antagonist-induced alteration of neuronal firing in prefrontal cortex. Biol Psychiatry (2007) 1.28
Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. Hillside J Clin Psychiatry (1987) 1.26
Reduced auditory evoked potential component N100 in schizophrenia--a critical review. Psychiatry Res (2008) 1.24
Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates. Synapse (1997) 1.23
The effects of ketamine vary among inbred mouse strains and mimic schizophrenia for the P80, but not P20 or N40 auditory ERP components. Neurochem Res (2004) 1.23
Deviance-elicited changes in event-related potentials are attenuated by ketamine in mice. J Cogn Neurosci (2008) 1.22
Central auditory dysfunction in schizophrenia as revealed by the mismatch negativity (MMN) and its magnetic equivalent MMNm: a review. Int J Neuropsychopharmacol (2008) 1.21
Behavioral lifetime of human auditory sensory memory predicted by physiological measures. Science (1992) 1.20
Abnormal auditory N100 amplitude: a heritable endophenotype in first-degree relatives of schizophrenia probands. Biol Psychiatry (2008) 1.19
Ketamine produces lasting disruptions in encoding of sensory stimuli. J Pharmacol Exp Ther (2005) 1.19
Demonstration of mismatch negativity in the monkey. Electroencephalogr Clin Neurophysiol (1992) 1.18
Effects of strain, novelty, and NMDA blockade on auditory-evoked potentials in mice. Neuropsychopharmacology (2002) 1.17
Source location of a 50 msec latency auditory evoked field component. Electroencephalogr Clin Neurophysiol (1988) 1.17
Combined mapping of human auditory EEG and MEG responses. Electroencephalogr Clin Neurophysiol (1998) 1.17
Heschl's gyrus, posterior superior temporal gyrus, and mid-ventrolateral prefrontal cortex have different roles in the detection of acoustic changes. J Neurophysiol (2006) 1.16
The NMDA antagonist model for schizophrenia: promise and pitfalls. Pharmacopsychiatry (1998) 1.14
Effects of an NMDA-receptor antagonist MK-801 on an MMN-like response recorded in anesthetized rats. Brain Res (2008) 1.12
Diminished responsiveness of ERPs in schizophrenic subjects to changes in auditory stimulation parameters: implications for theories of cortical dysfunction. Schizophr Res (1999) 1.10
A distributed cortical network for auditory sensory memory in humans. Brain Res (1998) 1.10
Nonprimary auditory thalamic representation of acoustic change. J Neurophysiol (1994) 1.10
Effect of ketamine on the neuromagnetic mismatch field in healthy humans. Brain Res Cogn Brain Res (2001) 1.09
Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis. Psychopharmacology (Berl) (2008) 1.09
Reversal of phencyclidine-induced dopaminergic dysregulation by N-methyl-D-aspartate receptor/glycine-site agonists. Neuropsychopharmacology (2004) 1.09
Temporal characteristics of auditory sensory memory: neuromagnetic evidence. Psychophysiology (1997) 1.08
In and out of the K-hole: a comparison of the acute and residual effects of ketamine in frequent and infrequent ketamine users. Addiction (2001) 1.07
The effects of a sub-anaesthetic dose of ketamine on human selective attention. Neuropsychopharmacology (2000) 1.05
Bursting of prefrontal cortex neurons in awake rats is regulated by metabotropic glutamate 5 (mGlu5) receptors: rate-dependent influence and interaction with NMDA receptors. Cereb Cortex (2005) 1.05
Deviance-related electrophysiological activity in mice: is there mismatch negativity in mice? Clin Neurophysiol (2005) 1.04
Midlatency auditory evoked responses in schizophrenia. Biol Psychiatry (1991) 1.03
Midlatency auditory event-related potentials in mice: comparison to midlatency auditory ERPs in humans. Brain Res (2004) 1.03
Multiple bilaterally asymmetric cortical sources account for the auditory N1m component. Brain Topogr (1998) 1.01
Auditory cortical event-related potentials to pitch deviances in rats. Neurosci Lett (1998) 1.01
Schizophrenia-like deficits in auditory P1 and N1 refractoriness induced by the psychomimetic agent phencyclidine (PCP). Clin Neurophysiol (2000) 1.01
Effects of chronic olanzapine and haloperidol differ on the mouse N1 auditory evoked potential. Neuropsychopharmacology (2004) 1.00
Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients. Curr Opin Psychiatry (2006) 1.00
Human auditory primary and association cortex have differing lifetimes for activation traces. Brain Res (1992) 1.00
NMDA antagonist effects on striatal dopamine release: positron emission tomography studies in humans. Synapse (2002) 1.00
Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach. Synapse (1998) 0.99
Spectral interactions, but no mismatch negativity, in auditory cortex of anesthetized rat. Hear Res (2003) 0.98
Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci (2008) 5.12
The leading sense: supramodal control of neurophysiological context by attention. Neuron (2009) 3.12
Multisensory auditory-visual interactions during early sensory processing in humans: a high-density electrical mapping study. Brain Res Cogn Brain Res (2002) 2.93
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry (2007) 2.89
Amplitude of low-frequency oscillations in schizophrenia: a resting state fMRI study. Schizophr Res (2009) 2.44
The initial field trials of DSM-5: new blooms and old thorns. Am J Psychiatry (2013) 2.39
Do you see what I am saying? Exploring visual enhancement of speech comprehension in noisy environments. Cereb Cortex (2006) 2.29
Subcortical visual dysfunction in schizophrenia drives secondary cortical impairments. Brain (2006) 2.26
Early-stage visual processing and cortical amplification deficits in schizophrenia. Arch Gen Psychiatry (2005) 2.25
Impaired visual object recognition and dorsal/ventral stream interaction in schizophrenia. Arch Gen Psychiatry (2002) 2.18
Auditory-somatosensory multisensory processing in auditory association cortex: an fMRI study. J Neurophysiol (2002) 2.12
The NKI-Rockland Sample: A Model for Accelerating the Pace of Discovery Science in Psychiatry. Front Neurosci (2012) 2.12
MRI study of white matter diffusion anisotropy in schizophrenia. Neuroreport (2003) 2.04
A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol Psychiatry (2010) 1.99
N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia? Brain Res Bull (2010) 1.98
Grabbing your ear: rapid auditory-somatosensory multisensory interactions in low-level sensory cortices are not constrained by stimulus alignment. Cereb Cortex (2004) 1.96
Multisensory visual-auditory object recognition in humans: a high-density electrical mapping study. Cereb Cortex (2004) 1.87
The spectrotemporal filter mechanism of auditory selective attention. Neuron (2013) 1.84
The role of spatial attention in the selection of real and illusory objects. J Neurosci (2007) 1.74
Sensory contributions to impaired prosodic processing in schizophrenia. Biol Psychiatry (2005) 1.74
The neural circuitry of pre-attentive auditory change-detection: an fMRI study of pitch and duration mismatch negativity generators. Cereb Cortex (2004) 1.73
Early-stage visual processing deficits in schizophrenia. Curr Opin Psychiatry (2005) 1.71
A roadmap for the development and validation of event-related potential biomarkers in schizophrenia research. Biol Psychiatry (2010) 1.62
The neural substrates of impaired prosodic detection in schizophrenia and its sensorial antecedents. Am J Psychiatry (2007) 1.61
D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry (2005) 1.59
Multisensory convergence in auditory cortex, I. Cortical connections of the caudal superior temporal plane in macaque monkeys. J Comp Neurol (2007) 1.58
Magnocellular pathway impairment in schizophrenia: evidence from functional magnetic resonance imaging. J Neurosci (2008) 1.57
A human intracranial study of long-range oscillatory coherence across a frontal-occipital-hippocampal brain network during visual object processing. Proc Natl Acad Sci U S A (2008) 1.51
Magnocellular contributions to impaired motion processing in schizophrenia. Schizophr Res (2005) 1.50
Amygdalofrontal functional disconnectivity and aggression in schizophrenia. Schizophr Bull (2009) 1.50
Prefrontal-subcortical dissociations underlying inhibitory control revealed by event-related fMRI. Eur J Neurosci (2004) 1.49
Sensory contributions to impaired emotion processing in schizophrenia. Schizophr Bull (2009) 1.48
Magnocellular and parvocellular contributions to backward masking dysfunction in schizophrenia. Schizophr Res (2003) 1.46
The spatiotemporal dynamics of illusory contour processing: combined high-density electrical mapping, source analysis, and functional magnetic resonance imaging. J Neurosci (2002) 1.45
A review of tolerability and abuse liability of gamma-hydroxybutyric acid for insomnia in patients with schizophrenia. Clin Ther (2009) 1.44
Auditory emotion recognition impairments in schizophrenia: relationship to acoustic features and cognition. Am J Psychiatry (2012) 1.41
Getting the cue: sensory contributions to auditory emotion recognition impairments in schizophrenia. Schizophr Bull (2008) 1.41
Timing of pure tone and noise-evoked responses in macaque auditory cortex. Neuroreport (2005) 1.41
Functional anatomy and interaction of fast and slow visual pathways in macaque monkeys. Cereb Cortex (2006) 1.40
DTI and impulsivity in schizophrenia: a first voxelwise correlational analysis. Neuroreport (2004) 1.38
Predicting success: patterns of cortical activation and deactivation prior to response inhibition. J Cogn Neurosci (2004) 1.37
Filling-in in schizophrenia: a high-density electrical mapping and source-analysis investigation of illusory contour processing. Cereb Cortex (2005) 1.35
Electrophysiological indices of automatic and controlled auditory information processing in first-episode, recent-onset and chronic schizophrenia. Biol Psychiatry (2006) 1.34
Early visual sensory deficits as endophenotypes for schizophrenia: high-density electrical mapping in clinically unaffected first-degree relatives. Arch Gen Psychiatry (2006) 1.34
High dose D-serine in the treatment of schizophrenia. Schizophr Res (2010) 1.33
Impairments in generation of early-stage transient visual evoked potentials to magno- and parvocellular-selective stimuli in schizophrenia. Clin Neurophysiol (2005) 1.32
Impaired multisensory processing in schizophrenia: deficits in the visual enhancement of speech comprehension under noisy environmental conditions. Schizophr Res (2007) 1.29
Dysfunction of early-stage visual processing in schizophrenia: harmonic analysis. Schizophr Res (2004) 1.26
Early sensory contributions to contextual encoding deficits in schizophrenia. Arch Gen Psychiatry (2011) 1.26
Sensory deficits and distributed hierarchical dysfunction in schizophrenia. Am J Psychiatry (2010) 1.25
"It's Not What You Say, But How You Say it": A Reciprocal Temporo-frontal Network for Affective Prosody. Front Hum Neurosci (2010) 1.23
Impaired visual object processing across an occipital-frontal-hippocampal brain network in schizophrenia: an integrated neuroimaging study. Arch Gen Psychiatry (2010) 1.23
Reading impairment and visual processing deficits in schizophrenia. Schizophr Res (2006) 1.22
Right hemisphere control of visuospatial attention: line-bisection judgments evaluated with high-density electrical mapping and source analysis. Neuroimage (2003) 1.22
Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr Bull (2007) 1.21
Visual backward-masking deficits in schizophrenia: relationship to visual pathway function and symptomatology. Schizophr Res (2003) 1.19
Theory of Mind (ToM) and counterfactuality deficits in schizophrenia: misperception or misinterpretation? Psychol Med (2006) 1.16
Anticipated, on-line and remembered positive experience in schizophrenia. Schizophr Res (2009) 1.16
Spatiotemporal dynamics of human object recognition processing: an integrated high-density electrical mapping and functional imaging study of "closure" processes. Neuroimage (2005) 1.13
Setting boundaries: brain dynamics of modal and amodal illusory shape completion in humans. J Neurosci (2004) 1.13
Decreased interhemispheric coordination in schizophrenia: a resting state fMRI study. Schizophr Res (2012) 1.10
Neurocognitive and symptom correlates of daily problem-solving skills in schizophrenia. Schizophr Res (2006) 1.10
Glutamatergic transmission in schizophrenia: from basic research to clinical practice. Curr Opin Psychiatry (2012) 1.09
What's in a face? Effects of stimulus duration and inversion on face processing in schizophrenia. Schizophr Res (2008) 1.08
Brain morphometry using diffusion-weighted magnetic resonance imaging: application to schizophrenia. Neuroreport (2005) 1.08
Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis. Schizophr Res (2004) 1.07
Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models. Clin Schizophr Relat Psychoses (2010) 1.06
Boundary completion is automatic and dissociable from shape discrimination. J Neurosci (2006) 1.05
Perceptual organization by proximity and similarity in schizophrenia. Schizophr Res (2007) 1.05
Voxelwise correlational analyses of white matter integrity in multiple cognitive domains in schizophrenia. Am J Psychiatry (2006) 1.05
Reduction in tonal discriminations predicts receptive emotion processing deficits in schizophrenia and schizoaffective disorder. Schizophr Bull (2011) 1.04
Activation of inhibition: diminishing impulsive behavior by direct current stimulation over the inferior frontal gyrus. J Cogn Neurosci (2011) 1.04
Pilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder. Int J Neuropsychopharmacol (2002) 1.04
Cortical thinning, functional connectivity, and mood-related impulsivity in schizophrenia: relationship to aggressive attitudes and behavior. Am J Psychiatry (2014) 1.03
High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol Psychiatry (2004) 1.02
Relation of plasma glycine, serine, and homocysteine levels to schizophrenia symptoms and medication type. Am J Psychiatry (2005) 1.02
Seeing the world dimly: the impact of early visual deficits on visual experience in schizophrenia. Schizophr Bull (2009) 1.02
Don't think of a white bear: an fMRI investigation of the effects of sequential instructional sets on cortical activity in a task-switching paradigm. Hum Brain Mapp (2004) 1.02
Early visual processing deficits in dysbindin-associated schizophrenia. Biol Psychiatry (2007) 1.01
Consequences of magnocellular dysfunction on processing attended information in schizophrenia. Cereb Cortex (2011) 1.01
A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression. Int J Neuropsychopharmacol (2012) 1.00
Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am J Psychiatry (2002) 0.99
Glycine treatment of the risk syndrome for psychosis: report of two pilot studies. Eur Neuropsychopharmacol (2012) 0.97
Altered volume and hemispheric asymmetry of the superficial cortical layers in the schizophrenia planum temporale. Eur J Neurosci (2009) 0.96
Predictive suppression of cortical excitability and its deficit in schizophrenia. J Neurosci (2013) 0.96
Changing plans: neural correlates of executive control in monkey and human frontal cortex. Exp Brain Res (2006) 0.95
Distinct neurophysiological mechanisms mediate mixing costs and switch costs. J Cogn Neurosci (2009) 0.95
Visual white matter integrity in schizophrenia. Am J Psychiatry (2006) 0.93
Differential relationships of mismatch negativity and visual p1 deficits to premorbid characteristics and functional outcome in schizophrenia. Biol Psychiatry (2011) 0.92
A new dimension of sensory dysfunction: stereopsis deficits in schizophrenia. Biol Psychiatry (2006) 0.92
Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder. J Affect Disord (2006) 0.92
Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia. Neuropsychopharmacology (2013) 0.92
GABAB/NMDA receptor interaction in the regulation of extracellular dopamine levels in rodent prefrontal cortex and striatum. Neuropharmacology (2009) 0.90
Hemispheric asymmetry and callosal integration of visuospatial attention in schizophrenia: a tachistoscopic line bisection study. Schizophr Res (2008) 0.90
Reversal of phencyclidine-induced prepulse inhibition deficits by clozapine in monkeys. Psychopharmacology (Berl) (2003) 0.90
A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia. J Clin Psychiatry (2012) 0.88
Contributions of low and high spatial frequency processing to impaired object recognition circuitry in schizophrenia. Cereb Cortex (2012) 0.88
Efference copy failure during smooth pursuit eye movements in schizophrenia. J Neurosci (2013) 0.87
Understanding tDCS effects in schizophrenia: a systematic review of clinical data and an integrated computation modeling analysis. Expert Rev Med Devices (2014) 0.87
Reading deficits in schizophrenia and individuals at high clinical risk: relationship to sensory function, course of illness, and psychosocial outcome. Am J Psychiatry (2014) 0.87